Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Cash from Operations: 2009-2025

Historic Cash from Operations for Myriad Genetics (MYGN) over the last 16 years, with Sep 2025 value amounting to $21.1 million.

  • Myriad Genetics' Cash from Operations rose 2914.29% to $21.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.2 million, marking a year-over-year increase of 96.86%. This contributed to the annual value of -$8.7 million for FY2024, which is 92.16% up from last year.
  • Myriad Genetics' Cash from Operations amounted to $21.1 million in Q3 2025, which was up 255.15% from -$13.6 million recorded in Q2 2025.
  • In the past 5 years, Myriad Genetics' Cash from Operations registered a high of $71.8 million during Q1 2021, and its lowest value of -$54.7 million during Q4 2023.
  • Its 3-year average for Cash from Operations is -$11.7 million, with a median of -$13.6 million in 2025.
  • Its Cash from Operations has fluctuated over the past 5 years, first plummeted by 1,029.55% in 2022, then skyrocketed by 2,914.29% in 2025.
  • Over the past 5 years, Myriad Genetics' Cash from Operations (Quarterly) stood at -$9.5 million in 2021, then rose by 23.16% to -$7.3 million in 2022, then crashed by 649.32% to -$54.7 million in 2023, then skyrocketed by 112.07% to $6.6 million in 2024, then soared by 2,914.29% to $21.1 million in 2025.
  • Its Cash from Operations stands at $21.1 million for Q3 2025, versus -$13.6 million for Q2 2025 and -$16.3 million for Q1 2025.